Positive Data from Onyx – Analyst Blog
Zacks Market Commentaries (December 9th, 2009) Writes:
Recently, Onyx Pharmaceuticals (ONXX) came out with positive data from a phase IIb study of carfilzomib at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. We are pleased to see that carfilzomib was found to be well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients. The company also stated that enrollment of 269 patients in this trial has been completed and data should be available in the second half of 2010. We believe favorable data could support a potential new drug application (NDA) filing by year-end 2010.
Additionally, Onyx reported safety data from another study that showed carfilzomib can be used in patients over a long period of time even for those who are suffering from other illnesses. Carfilzomib was added to Onyx’s portfolio following the company’s acquisition of Proteolix for an upfront cash payment of $276 million during the third quarter of
...

![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)


